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Abstract
Conotruncal heart defects (CTDs) are among the most common and severe groups of con-
genital heart defects. Despite evidence of an inherited genetic contribution to CTDs, little is
known about the specific genes that contribute to the development of CTDs. We performed
gene-based genome-wide analyses using microarray-genotyped and imputed common and
rare variants data from two large studies of CTDs in the United States. We performed two
case-parent trio analyses (N = 640 and 317 trios), using an extension of the family-based
multi-marker association test, and two case-control analyses (N = 482 and 406 patients and
comparable numbers of controls), using a sequence kernel association test. We also under-
took two meta-analyses to combine the results from the analyses that used the same
approach (i.e. family-based or case-control). To our knowledge, these analyses are the first
reported gene-based, genome-wide association studies of CTDs. Based on our findings, we
propose eight CTD candidate genes (ARF5, EIF4E, KPNA1, MAP4K3, MBNL1, NCAPG,
NDFUS1 and PSMG3). Four of these genes (ARF5, KPNA1, NDUFS1 and PSMG3) have
not been previously associated with normal or abnormal heart development. In addition, our
analyses provide additional evidence that genes involved in chromatin-modification and in
ribonucleic acid splicing are associated with congenital heart defects.
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Introduction
Congenital heart defects (CHDs) are the most common group of birth defects, with a preva-
lence of approximately 1% in live births [1]. CHDs are also the leading cause of birth defect
related mortality [2] and account for the largest percentage of birth defect associated hospitali-
zations and hospitalization-associated costs [3]. In the United States, it is estimated that there
are approximately 2.4 million CHD survivors (1.4 million adults, 1 million children) [4], the
majority of whom will require lifelong cardiac care. Despite the impact on affected patients,
their families, and the healthcare system, the causes of CHDs are not well defined [5].
There are many different CHD phenotypes, of which approximately one-third involve the
cardiac outflow tracts and great arteries [6]–structures that develop from the cardiac neural
crest and secondary heart field [7]. This subgroup of CHDs, collectively referred to as cono-
truncal heart defects (CTDs), includes some of the most severe and costly birth defects [3, 8].
In addition to their shared embryologic and anatomic basis, there is substantial evidence that
the various CTD phenotypes (e.g. tetralogy of Fallot (TOF), truncus arteriosus) share common
genetic underpinnings. For example, nationwide, population-based studies conducted in Nor-
way and Denmark indicate that CTDs aggregate within families (recurrence risk ratios for
CTDs in first-degree relatives: 9–12) [9, 10] and that affected relatives of patients with a CTD
are at a higher relative risk for CTDs (sibling CTD recurrence risk ratio: 9.0, 95% confidence
interval (CI) 4.0–20.0) than for other types of CHDs (sibling non-CTD, CHD recurrence risk
ratio: 3.6, 95% CI 2.4–5.5) [9]. Further, there is evidence that, within affected relative-pairs, the
specific type of CTD can differ. For example, among 28 CTD-affected siblings of patients with
TOF, 17 also had TOF whereas 11 had a different CTD phenotype [11]. Additional evidence
that the various CTD phenotypes share a common genetic basis is provided by the phenotypic
characteristics of defined genetic syndromes. For example, in patients with the 22q11.2 dele-
tion syndrome, the most common cardiac defects are CTDs, but the specific CTD phenotype
(e.g. TOF, interrupted aortic arc) varies across patients with this deletion [12].
Studies of syndromes that include CTDs, such as the 22q11 deletion syndrome, have pro-
vided some clues regarding the specific genes that may be involved in determining the risk of
CTDs (e.g. TBX1 [13]). In addition, studies of rare, presumably pathogenic, copy number vari-
ants [14–16], and inherited [17] and de novo [17, 18] single nucleotide variants have identified
genes that may contribute to the risk of CTDs [18, 19]. Yet, most affected patients do not carry
a confirmed or suspected rare, causative variant. Moreover, rare variants, in particular rare de
novo variants, do not account for the observed increase in risk of CTDs among the relatives of
affected patients.
Since rare, pathogenic variants are unlikely to fully account for the population prevalence
or familial recurrence of CTDs, additional genetic mechanisms must also contribute to disease
risk. While the involvement of more common variants that have more moderate impacts on
CTD risk seems likely, genome-wide association studies (GWAS) [20–23] of common single
nucleotide polymorphisms (SNPs) have identified only two genome-wide significant associa-
tions for CTDs (rs11065987, p = 7.7E-11 and rs7982677, p = 3.03E-11) [22]. However, given
the huge number of variants evaluated in GWAS, the threshold for statistical significance is
quite stringent (i.e. p<5E-08). Consequently, the lack of significant findings for CTDs may
well reflect low study power rather than the lack of common, CTD-related genetic variants.
Gene-based GWAS provide an additional strategy for identifying disease-related genes, but,
to our knowledge, there are no published gene-based GWAS for CTDs. Compared to SNP-
based GWAS, gene-based studies have the advantage of a less stringent threshold for statistical
significance (e.g. Bonferroni corrected p-value for 20,000 genes, 2.5E-06). In addition, SNP-
based analyses generally exclude rare variants, due to low statistical power [24], whereas gene-
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based analyses can incorporate data from both common and rare variants [25] and, therefore,
capture more genomic variation than SNP-based analyses. Given these advantages, we have
undertaken gene-based analyses and meta-analyses using data from several large CTD
datasets.
Materials and methods
Study subjects
The Children’s Hospital of Philadelphia (CHOP). Informed consent was obtained
under a protocol approved by the Institutional Review Board for the protection of human sub-
jects at CHOP. Adult subjects (parents or guardians) provided written consent for themselves
and their minor children. Patients diagnosed with CTDs and their available parents of all races
and ethnicities were recruited through the Cardiac Center at CHOP from 1992–2010 [21].
Patients with the following diagnoses were included in the study: TOF, persistent truncus
arteriosus, D-transposition of great arteries (TGA), double outlet right ventricle, ventricular
septal defects (conoventricular, posterior malalignment and conoseptal hypoplasia types), aor-
tic-pulmonary window, interrupted aortic arch and isolated aortic arch anomalies. Cardiac
diagnoses were confirmed using medical and operative reports as well as imaging (e.g., echo-
cardiography, cardiac magnetic resonance imaging, cardiac catheterization) records. All
potential patients were tested for the 22q11.2 deletion syndrome using fluorescence in situ
hybridization and/or multiplex ligation-dependent probe amplification using standard tech-
niques. Patients with a confirmed 22q11.2 deletion were excluded [26]. Patients with a clini-
cally diagnosed chromosomal abnormality, single gene mutation, teratogenic syndrome or
known maternal risk factor (e.g. diabetes, anticonvulsant use) were also excluded [21].
The CHOP patients were previously microarray genotyped in two phases. In the first phase,
cases with any CTD phenotype and of any race and ethnicity, and their parents were geno-
typed to generate data for a case-parent trio study. In the second phase, only non-Hispanic
Caucasian cases (based on self- or parental-reported race/ethnicity) were genotyped to gener-
ate data for a case-control study. Control data were obtained from existing microarray geno-
typed data from pediatric controls that were recruited during well child visits at CHOP [27].
Pediatric Cardiac Genomics Consortium (PCGC). Informed consent was obtained from
each participating individual or their parent or guardian in accordance with protocols
approved by the Institutional Review Board of each participating institution. Patients with a
CHD and their available parents of all races and ethnicities were recruited as part of the PCGC
Congenital Heart Defect GEnetic NEtwork Study from 2010–2012 [18, 28, 29]. PCGC recruit-
ment took place at five main clinical sites (including CHOP) and four satellite clinics. The
patients recruited by PCGC through CHOP do not overlap with the CHOP patients described
above. Participant information was collected through medical records, electronic case reports,
and personal interviews. Our studies were restricted to include patients with a CTD (as
described above) and without a clinically diagnosed chromosomal or genetic disorder.
Genetic methods
Blood samples were collected from each patient and pediatric control. When blood collection
was scheduled in conjunction with a surgical procedure, the sample was collected prior to any
blood transfusion. Blood or saliva samples were collected from available parents of patients.
DNA extraction was performed using standard techniques.
Genome-wide microarray genotyping was performed at the CHOP Center for Applied
Genomics. Samples collected at CHOP were genotyped using Illumina HumanOmni-2.5 or
Illumina HumanHap550 (v2, v3), or 610 BeadChip platforms. Samples collected as part of the
Gene-based GWAS and meta-analysis of conotruncal heart defects
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PCGC (including the PCGC samples collected at CHOP) were genotyped on the Illumina
HumanOmni-1 or HumanOmni-2.5 platforms. Additional details regarding the CHOP and
PCGC samples are provided elsewhere [18, 21, 27, 28].
Imputation and quality control (QC) procedures
The microarray genotyped data from CHOP and PCGC were imputed using Impute2 v2.3.0
and pre-phased haplotype data obtained from the 1000 Genomes Project (Phase-I integrated
v3 variants set) as the reference [30]. Due to differences in the genotyping platforms, the
CHOP and PCGC cohorts were imputed separately.
Standard QC procedures were performed for each dataset using PLINKv1.07 before and
after imputation [31]. Before imputation, the array data were checked for strand and coding
errors. Trios were removed if more than 1% of genotyped SNPs had Mendelian errors. Sus-
pected duplicate samples were identified using pairwise identify-by-descent estimation and
samples with pi-hat greater than 0.6 were removed. Samples with genotyping rates less than
95% were also removed. In addition, variants with minor allele frequency (MAF) less than 1%,
genotyping rates less than 90%, or deviation from Hardy Weinberg Equilibrium (HWE) in
controls (p<1E-05) were excluded, as were all non-autosomal variants.
After the pre-imputation exclusions, the CHOP data from different platforms (HumanOmni-
2.5, HumanHap550K v2, 550K v3 and 610K) were combined and only those variants present on
all platforms (N = 283,977 SNPs) were used for imputation. Similarly, the PCGC data from differ-
ent Illumina platforms (HumanOmni-1 and HumanOmni-2.5) were combined and only those
SNPs present on both platforms (N = 624,419 SNPs) were used for imputation. For each dataset,
haplotypes were pre-phased using SHAPEIT2 v2.727 [32] and imputation was performed using
Impute2 v2.3.0 [30]. A genotype was imputed only if the posterior probability value exceeded 0.9,
the default calling threshold for Impute2. After imputation, we excluded variants with poor impu-
tation quality (Impute2 information metric score<0.8), or genotyping rates less than 90%. Sam-
ples with genotyping rates less than 95% and all insertions or deletions were removed. For all case-
control comparisons, variants were evaluated for deviation from HWE in the pediatric control
group using the exact test [33] implemented in PLINK, and variants with p<1E-05 were excluded.
Because we were interested in assessing both rare and common variants, the post-imputation QC
procedures did not include restrictions based on MAFs.
Statistical analysis
Genome-wide gene-based analyses were conducted, as described below. Because the various
gene-based approaches have different underlying assumptions, strengths and limitations, we
used two different gene-based approaches, eFBAT-MM and SKAT-C, to optimize the proba-
bility of identifying CTD-related genes. All analyses included all autosomal RefSeq genes,
defined by the transcription start-stop coordinates (Genome Reference Consortium Human
genome build 37 or hg19 reference assembly) in the RefSeq gene records and we included vari-
ants that were 1kb upstream or downstream of each gene.
Family-based analyses. Data for case-parent trios ascertained through CHOP (CHOP-
Trios) and PCGC (PCGC-Trios) trios were analyzed separately using an extension of the fam-
ily-based multi-marker association test (eFBAT-MM) [34]. This test (i.e. eFBAT-MM) is a bur-
den-type approach that collapses variant-level statistics over a gene or region to obtain a single
p-value and makes the assumption that all associated variants in the gene or genetic region
affect the phenotype in the same direction. The variants were weighted by the inverse of the
MAF estimated from the parental genotypes. Meta-analysis of the gene p-values from the
CHOP and PCGC trios was performed using Fisher’s combination of probability method [35].
Gene-based GWAS and meta-analysis of conotruncal heart defects
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Case-control analyses. For the present study, we formed two independent, case-control
(CC) datasets using the microarray genotyped and imputed data from CHOP. The first dataset
included the Caucasian subset of patients from the CHOP trios and an equal number of Cau-
casian pediatric controls (CHOP-CC1). The second dataset included a second set of Caucasian
patients with a CTD and an equal number of Caucasian pediatric controls (CHOP-CC2).
There was no overlap in the cases or the controls included in CHOP-CC1 and CHOP-CC2.
The two CHOP case-control datasets (CHOP-CC1 and CHOP-CC2) were analyzed sepa-
rately using the sequence kernel association test for the combined effect of common and rare
variants (SKAT-C) [36]. Using this approach, separate scores were calculated for rare and
common SNPs and these scores were combined as a weighted sum to calculate the gene p-
value. The SKAT-C recommended default parameters were used for variant weighting and
analysis. To control for population stratification bias, only non-Hispanic Caucasian cases
(based on self- or parental report) were included in the analyses. Since race and ethnicity were
based on self-report (rather than ancestry informative genetic markers), each analysis was also
adjusted for the first genotypic principal component. Genotypic principal component analyses
were conducted in Golden Helix SVS8.1, using the default parameter settings (MAF-based
allele classification, additive genetic model and data for each marker were normalized by its
theoretical standard deviation under HWE) (Golden Helix, Inc., Bozeman, MT, www.
goldenhelix.com). Meta-analysis of the gene p-values from the two case-control series was per-
formed using Fisher’s combination of probability method [35]. Meta-analyses combining
results from the eFBAT-MM and SKAT-C analyses were not performed, given the overlap in
patients (i.e. the non-Hispanic Caucasian cases in the CHOP-Trios are the case group for
CHOP-CC1) and the differences in the assumptions underlying the two analytic approaches.
For each of the family-based and case-control analyses, the genomic inflation factor (λ) was
calculated (for the case-control analyses, λwas calculated using values that adjusted for the first
genotypic principal component) and a quantile-quantile (Q-Q) plot was constructed to check
for deviation of the genome-wide observed distribution of the test statistic from the expected
null distribution. Genes with association p-values less than the Bonferroni-corrected p-value
(based on the number of genes in each analysis) were considered genome-wide significant.
Genes with p-values greater than the Bonferroni-corrected p-values but less than 1E-03 were
considered to be suggestive of an association.
Gene-set enrichment analysis. Genes with p<0.01 in the eFBAT-MM or SKAT-C meta-
analyses were evaluated together for gene-annotation enrichment using MetaCoreTM (Thom-
son Reuters, Life Science Research, https://portal.genego.com/metacore). A false-discovery
rate (FDR) corrected p-value less than 0.05 was used to identify significant pathway maps and
Gene Ontology (GO) processes. REVIGO was used for clustering GO terms based on p-values
and semantic similarity score (simRel) [37]. The simRel scores range from 0 to 1 and we used
a score threshold of 0.4 for filtering GO terms.
Gene annotation and prioritization. To prioritize genes with at least suggestive evidence
of association with CTD (p<1E-3, in either the family-based or case-control meta-analysis),
for future investigations, we considered: (1) whether the meta-analysis p-value for the gene
was lower than the p-values in contributing datasets i.e. the evidence for association was stron-
ger in the combined data than in either of the individual datasets; and, (2) gene expression lev-
els, based on heart expression data from E9.5 and E14.5 mouse embryos [18]. For each gene
with a meta-analysis p-value lower than the p-values for the contributing datasets, we anno-
tated the variants that were included in our analyses, for location, function, MAF in the
genome aggregation database [38], Combined Annotation Dependent Depletion (CADD)
phred-scaled scores [39], Genome-Wide Annotation of VAriants (GWAVA) [40] and Geno-
mic Evolutionary Rate Profiling scores [41]. Genes with meta-analysis p-values lower than the
Gene-based GWAS and meta-analysis of conotruncal heart defects
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p-values from the contributing datasets, and with heart expression data in the top quartile at
E9.5 or E14.5 were considered strong candidates for future investigations.
Results
After QC exclusions, there were 640 CHOP trios and 317 PCGC trios for family-based analyses
(Fig 1). In addition, there were 482 patients with CTD and 483 controls for CHOP-CC1, and
406 patients with CTD and 406 controls for CHOP-CC2. In both sets of trios, patients were
predominantly Caucasian (Table 1). The two case-control datasets were restricted to Cauca-
sians participants. In all groups, the most common heart defect was TOF.
Gene-based GWAS of individual datasets
The number of variants and genes included in each analysis are summarized in Table 2. The
genotype concordance for the imputation was >90%. The Q-Q plots (S1–S4 Figs) and geno-
mic inflation factors (Table 2) provided little evidence for systematic bias in the observed p-
values. No genome-wide significant associations were identified in the analyses of the individ-
ual datasets. The number of genes with suggestive evidence of association (p<1E-03) ranged
from 13 to 27 (Table 2). There was no overlap across datasets or analyses with respect to the
genes with suggestive evidence of association. Detailed genome-wide results for each analysis
are included in Tables B-E in S1 File.
Fig 1. Summary of conotruncal heart defects data cohorts. The participants were recruited from the Children’s Hospital of Philadelphia (CHOP) and the
Pediatric Cardiac Genomics Consortium (PCGC). CHOP-Trios and PCGC-Trios were analyzed using eFBAT-MM whereas SKAT-C was used to analyze
the two case-control cohorts (CHOP-CC1 and CHOP-CC2). The cases in CHOP-CC1 are the Caucasian subset of cases in CHOP-Trios. One of 483
Caucasian cases was excluded during QC procedures prior to SKAT-C analysis.
https://doi.org/10.1371/journal.pone.0219926.g001
Gene-based GWAS and meta-analysis of conotruncal heart defects
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Meta-analysis
Separate meta-analyses were conducted using eFBAT-MM p-values for 21,170 genes that were
analyzed in both the CHOP and PCGC trios, and from SKAT-C p-values for 21,077 genes that
were analyzed in both the CHOP-CC1 and CHOP-CC2 case-control studies. The Q-Q plots
(Figs 2 and 3) and genomic inflation factors provided little evidence for systematic bias in the
observed p-values. No gene achieved genome-wide significance in either meta-analysis
(Table F in S1 File provides p-values for all genes assessed in each meta-analysis). Suggestive
evidence of association (p<1E-03) was obtained for 11 genes (8 protein coding, 2 pseudogenes,
1 RNA gene) in the trio-based meta-analysis (Table 3) and for 27 genes (23 protein coding, 4
RNA genes) in the case-control based meta-analysis (Table 4).
We identified genes that have previously been implicated in heart development and struc-
tural heart malformations (e.g. MBNL1, ROR1), and known disease-related genes (e.g. NEXN,
dilated cardiomyopathy; NDUFS1, mitochondrial complex I deficiency). Several of the identi-
fied genes are also annotated to biological processes that are important during embryonic
heart development including transcription (FUBP1, POU6F2, MKX), protein phosphorylation
(MAP4K3, PRKD2, ROR1, STK33), positive regulation of the ERK1 and ERK2 cascade (ROR1,
PRKD2), Wnt signaling (ROR1, DACT3), and cell adhesion (PRKD2, SYMPK).
Gene-set enrichment analysis
MetaCoreTM gene-set enrichment analysis was performed using genes with p<0.01 in the trio
(195 genes) or case-control (246 genes) based meta-analyses (Table F in S1 File). We identified
two significantly enriched pathways (FDR-corrected p<0.05): dynein-dynactin motor com-
plex in axonal transport in neurons (FDR-corrected p = 0.02), and chromosome condensation
in prometaphase (FDR-corrected p = 0.02) (Table G in S1 File). In addition, we identified 111
Table 1. Characteristics of patients with conotruncal defects in the Children’s Hospital of Philadelpia (CHOP) and Pediatric Cardiac Genomics Consortium
(PCGC) datasets.
N (%)
CHOP-Trios /
CHOP-CC1a
(n = 640)
CHOP-CC2
(n = 406)
PCGC-Trios
(n = 317)
Race/ethnicity
Non-Hispanic Caucasian 483 (75.5) 406 (100.0) 244 (70.1)
Other 157 (24.5) 0 (0.0) 73 (29.9)
Sex
Male 387 (60.5) 236 (58.1) 192 (60.6)
Female 253 (39.5) 170 (41.9) 125 (39.4)
Conotruncal defect phenotype
Tetralogy of Fallot 250 (39.1) 134 (33.0) 104 (32.8)
D-transposition of the great arteries 125 (19.5) 80 (19.7) 64 (20.2)
Ventricular septal defects 133 (20.8) 109 (26.8) 44 (13.9)
Double outlet right ventricle 66 (10.3) 25 (6.2) 46 (14.5)
Isolated aortic arch anomalies 30 (4.7) 22 (5.4) 7 (2.2)
Persistent truncus arteriosus 18 (2.8) 19 (4.7) 13 (4.1)
Interrupted aortic arch 11 (1.7) 10 (2.5) 9 (2.8)
Other 7 (1.1) 7 (1.7) 30 (9.5)
aThe cases used in CHOP-CC1 are the subset of the cases included in the CHOP-Trios (i.e. the non-Hispanic Caucasian cases, N = 483).
https://doi.org/10.1371/journal.pone.0219926.t001
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significantly enriched (FDR-corrected p<0.05) non-redundant (REVIGO-clustered) GO pro-
cesses (Table H in S1 File). GO term clusters included processes relevant to heart defects
including cellular response to hormone stimulus, angiogenesis and biological adhesion.
Gene annotations and prioritization
Of the 38 genes with suggestive evidence of association (p<1E-3) in either the family-based or
case-control meta-analysis, 19 protein-coding and 2 RNA genes had a lower meta-analysis p-
value than the p-values in contributing datasets i.e. the evidence for association was stronger
in the combined data than in either individual dataset (Table 5). For the 21 genes with meta-
analysis p-value less than the individual study p-values, the majority (95%) of variants included
in the analyses were intronic (Table I in S1 File). Heart expression data from E9.5 and E14.5
mouse embryos [18] were available for 15 of the 19 protein-coding genes, of which eight (53%)
were in the top quartile of expression at one or both time points (Table 5). We propose these
eight genes (ARF5, EIF4E, KPNA1, MAP4K3, MBNL1, NCAPG, NDFUS1, PSMG3) as CTD
candidate genes.
Table 2. Summary of eFBAT-MM and SKAT-C analyses and results.
eFBAT-MM SKAT-C
CHOP-Trios PCGC Trios CHOP-CC1 CHOP-CC2
Total variants 5,578,860 6,812,971 5,601,587 5,601,152
Rare variantsa 3,446,735 4,502,285 3,502,419 3,495,988
Number of genes 21,256 22,247 21,212 21,269
Genomic inflation factor (λ) 1.03 1.04 1.09 1.09
Genes with p<1E-03b 13 13 25 27
CBLN2
C22orf39
NCOA2
CEP95
DDX5
SQRDL
SLMO2-ATP5E
TRIP13
PADI3
RBM47
PRR14
ZC3H18
CREBZF
MIR518C
GOLGA2P9
POU6F2
LCE4A
TMEM206
LOC100996349
ASAH2
MBNL1
IGFBPL1
RNF44
IRAK2
DDX59
ADGRA3
FAM225A
ABCB4
STK33
BLOC1S6
MIR3916
LEXM
DACT3
MIR99AHG
TRIP10
LINC00620
DACT3-AS1
NPPC
GPATCH1
AVPR1A
FLNC
NCAPG
SHD
ARAP3
FIGN
NCAN
SYMPK
MIR548AA2
MIR548D2
BHMG1
FCGR3B
PSMG3
NEXN
FUBP1
PSMG3-AS1
DNAJB4
TSSC4
TSPAN10
MKX-AS1
MKX
UHMK1
ATG9B
MMP19
CRTAM
NPLOC4
GRID2
COPZ2
PTPRT
PYGL
COA5
EEF1B2
APOPT1
GATC
ACTL7B
NDUFS1
LOC101927653
AACS
EPHB4
a Variants with minor allele frequency <0.05
b Genes are listed by p-value (lowest to highest). Specific p-values are provided in Tables B-E in S1 File.
https://doi.org/10.1371/journal.pone.0219926.t002
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Discussion
Our comprehensive genome-wide, gene-based analysis of common and rare variants identified
38 genes with suggestive evidence of association (meta-p<1E-3) with CTDs, as well as relevant
biological pathways and processes that were significantly enriched (FDR-corrected p<0.05)
among the genes with the most significant p-values in gene-based analyses. Based on both sta-
tistical evidence (i.e. the evidence for association was stronger in the meta-analysis than in any
of the contributing studies) and gene expression data (top quartile of expression in mouse
heart at E9.5 or E14.5) we propose eight genes (ARF5, EIF4E, KPNA1, MAP4K3, MBNL1,
NCAPG, NDFUS1, PSMG3) as CTD candidate genes.
Fig 2. Quantile-quantile plot of eFBAT-MM test gene-level meta-analysis p-values.
https://doi.org/10.1371/journal.pone.0219926.g002
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Four of the CTD candidate genes suggested by our work have not been associated with nor-
mal or abnormal heart development. These four genes are: ADP ribosylation factor 5 (ARF5),
which encodes a GTP-binding protein involved in protein trafficking; karyopherin subunit
alpha 1 (KPNA1), which functions in nuclear protein import; NADH:Ubiquinone oxidoreduc-
tase core subunit protein coding S1 (NDUFS1), which encodes the core subunit of the mito-
chondrial membrane respiratory chain NADH dehydrogenase, and; proteasome assembly
chaperone 3 (PSMG3), which encodes a chaperone protein.
The known function of the remaining four candidate genes suggests that their altered
expression could cause CHDs. Of these genes, the most significant association was observed
Fig 3. Quantile-quantile plot of SKAT-C test gene-level meta-analysis p-values.
https://doi.org/10.1371/journal.pone.0219926.g003
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for muscleblind-like splicing regulator 1 (MBNL1, eFBAT-MM meta-p = 1.5E-04). This gene
encodes a CH3-type zinc finger protein (MBNL1) that is a key regulator of pre-RNA alterna-
tive splicing. Evidence that splicing regulators contribute to the etiology of CHDs is provided
by the identification of a genome-wide, significant excess of damaging de novo and loss-of-
function heterozygous mutations in another key splicing regulator, RBFOX2, in patients with
CHDs [17].
Several additional lines of evidence also support a role for MBNL1 in cell differentiation
and heart development. For example, MBNL1 and RBFOX2 appear to co-regulate the splicing
changes that lead to the differentiation of pluripotent stem cells [42]. In addition, in the nucle-
otide repeat expansion disorder, myotonic dystrophy, reduced MBNL1 splicing activity (due
to binding of MBNL1 protein to the expansion RNA) is thought to play a major role in deter-
mining the disease phenotype, which includes several cardiovascular abnormalities (conduc-
tion defects, arrhythmias, mitral valve prolapse) [43, 44]. There is also evidence that MBNL1 is
involved in the fetal to adult transition in alternative splicing patterns in the heart [45], and
that MBNL1 negatively regulates TGF-β signaling and the epithelial-mesenchymal transition
in the endocardial cushions by restricting the timing and amount of TGF- β production in the
atrioventricular canal and outflow tract endocardium [46, 47]. Mice null for MBNL1 protein
present with abnormal heart valve development, regurgitation across both the in- and outflow
valves, and ostium secundum septal defects [47].
Further evidence that genes involved in RNA splicing may be associated with CTDs is pro-
vided by our gene-set enrichment analyses. Specifically, genes mapping to the GO process ‘reg-
ulation of RNA splicing’ (GO:0043484) were significantly enriched (FDR-adjusted p = 0.03)
among genes with association p<0.01 in our meta-analyses. In addition to MBNL1, seven
genes mapping to this process (CLK3, DDX5, JMJD6, SRSF2, SRSF9 and TMBIM6) had meta-
analysis p<0.01 (meta-analysis p-value range: 2E-03 to 8E-03) in either the family-based (i.e.
eFBAT-MM) or case-control (i.e. SKAT-C) meta-analysis.
The second most significant of our proposed CTD candidate genes was eukaryotic transla-
tion initiation factor 4D (EIF4E, SKAT meta-p = 3.6E-04). The encoded protein, eIF4F, directs
ribosomes to the mRNA 5’-cap and is a key factor in initiation of translation of many mRNAs
[48]. Zhang et al. have presented evidence that eIF4E is involved in heart development via the
p53-Rbm24 loop [49]. Specifically, they demonstrated that the multifunctional RNA-binding
Table 3. Genes with suggestive evidence of association (p<1E-03) in the trio-based meta-analysis.
CHOP-Trios
(640 trios)
PCGC-Trios
(317 trios)
Meta-analysis
Gene Function Number of variants p-valuea Number of variants p-valuea p-value
POU6F2 Protein coding 2,662 8.9E-02 2,738 8.7E-05 9.8E-05
MBNL1 Protein coding 534 3.3E-02 789 3.7E-04 1.5E-04
SIGLEC11 Protein coding 37 4.1E-03 53 3.1E-03 1.6E-04
GOLGA2P9 Pseudogene 38 9.8E-01 83 2.3E-05 2.7E-04
MAP4K3 Protein coding 1,020 1.6E-03 1,063 2.1E-02 3.7E-04
CBLN2 Protein coding 39 2.4E-04 52 1.5E-01 4.1E-04
ROR1 Protein coding 1,585 2.4E-02 1,954 2.0E-03 5.3E-04
LINC00207 RNA gene 26 2.0E-02 25 2.9E-03 6.2E-04
KPNA1 Protein coding 317 5.4E-02 352 1.5E-03 8.4E-04
GLIPR1 Protein coding 81 2.9E-02 104 2.9E-03 8.6E-04
LOC100996349 Pseudogene 7 4.2E-01 15 2.0E-04 8.8E-04
a gene-level p-values from eFBAT-MM test
https://doi.org/10.1371/journal.pone.0219926.t003
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protein, Rbm24, prevents binding of eIF4E to p53 RNA, thereby repressing p53 translation
and p53-dependent apoptosis. Further, they showed that mice deficient for Rbm24 develop
endocardial cushion defects as a result of aberrant binding of eIF4E to p53 RNA resulting in
overexpression of p53. Mutations in EIF4E have also been implicated as a cause of autism in
humans [50], and enhanced eIF4E activity has been associated with autism-like phenotypes in
animal models [51]. Hence, our finding adds EIF4E to the growing list of genes that may be
related to both CHDs and neurodevelopment disabilities such as autism [17, 52].
Our study also identified the mitogen-activated protein kinase kinase kinase kinase 3
(MAP4K3) as a CTD candidate gene. The product of this gene is an upstream activator of the
c-Jun-N-terminal kinase (JNK) signal transduction pathway, which is involved in several pro-
cesses relevant to heart development (e.g. cell growth, differentiation and survival, apoptosis)
[53]. Downstream effectors of JNK signaling relevant to heart development include the tumor
suppressor/apoptosis gene, p53 (discussed above), and SMAD4. In a mouse model, disruption
of Smad4 in neural crest cells resulted in multiple malformations including defects of the out-
flow tracts and ventricles [54]. Further, in humans, SMAD4 gain of function mutations cause
Table 4. Genes with suggestive evidence of association (p<1E-03) in the case-control based meta-analysis.
CHOP-CC1
(482 CTD patients/483 controls)
CHOP-CC2
(406 CTD patients/ 406 controls)
Meta-analysis
Gene Function Number of variants p-valuea Number of variants p-valuea p-value
PSMG3 Protein coding 41 6.5E-02 40 2.6E-05 2.4E-05
FAM225A RNA gene 6 3.9E-05 7 5.3E-02 2.9E-05
ABCB4 Protein coding 252 9.9E-05 272 9.5E-02 1.2E-04
LEXM Protein coding 208 2.5E-04 185 4.2E-02 1.3E-04
SHD Protein coding 28 6.9E-04 31 1.8E-02 1.5E-04
NEXN Protein coding 150 5.1 E-01 162 3.0E-05 1.9E-04
LOC100287036 Protein coding 12 6.3E-03 15 2.5E-03 1.9E-04
PSMG3-AS1 RNA gene 29 1.8 E-01 28 1.1E-04 2.3E-04
PRKD2 Protein coding 59 1.2E-03 67 2.3E-02 3.1E-04
DACT3 Protein coding 16 3.1E-04 14 9.1E-02 3.2E-04
EIF4E Protein coding 237 2.6E-02 271 1.2E-03 3.6E-04
MKX-AS1 RNA gene 66 1.8 E-01 80 1.8E-04 3.6E-04
MKX Protein coding 323 1.5 E-01 406 2.2E-04 3.7E-04
RGS16 Protein coding 11 5.3E-03 11 6.7E-03 4.0E-04
CHODL Protein coding 1,101 2.8E-02 1,396 1.3E-03 4.2E-04
NCAPG Protein coding 76 6.8E-04 84 5.5E-02 4.2E-04
DNAJB4 Protein coding 43 3.3 E-01 44 1.2E-04 4.4E-04
FUBP1 Protein coding 79 8.1 E-01 91 5.2E-05 4.7E-04
DACT3-AS1 RNA gene 14 4.7E-04 12 9.5E-02 4.9E-04
STK33 Protein coding 769 1.1E-04 784 5.7 E-01 6.4E-04
DCAF16 Protein coding 22 1.7E-03 28 4.0E-02 7.2E-04
ACTL7B Protein coding 21 9.5E-02 20 7.5E-04 7.5E-04
NDUFS1 Protein coding 181 8.6E-02 192 8.8E-04 8.0E-04
FBXO47 Protein coding 66 2.2E-03 52 3.7E-02 8.4E-04
ARF5 Protein coding 25 3.8E-03 24 2.2E-02 8.7E-04
PYGL Protein coding 114 1.7 E-01 112 5.4E-04 9.5E-04
SYMPK Protein coding 234 7.8E-04 251 1.2 E-01 9.9E-04
a gene-level p-values from SKAT-C
https://doi.org/10.1371/journal.pone.0219926.t004
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Myhre syndrome, which includes CHD as a common (~2/3rds of patients) phenotypic finding
[55]. There is also evidence that MAP4K3 is a central regulator of autophagy, a process that is
critical for maintaining the supply of free amino acids for protein synthesis [56] that is
required for embryonic growth and development.
Table 5. Genes with suggestive evidence of association (p<1E-03) in either dataset and with a meta-analysis p-value that is lower than that obtained in either of the
contributing analyses.
Gene Gene Name Function Gene-based
Test
Dataset 1 p-
valuea
Dataset 2 p-
valuea
Meta-analysis p-
value
Day
9.5b
Day
14.5b
ARF5 ADP-ribosylation factor 5 Protein-
coding
SKAT-C 3.84E-03 2.17E-02 8.67E-04 95.3 88.8
CHODL Chondrolectin Protein-
coding
SKAT-C 2.80E-02 1.32E-03 4.15E-04 5.8 10.4
DCAF16 DDB1 and CUL4 associated factor 16 Protein-
coding
SKAT-C 1.70E-03 3.98E-02 7.18E-04 No
data
No
data
EIF4E Eukaryotic translation initiation factor
4E
Protein-
coding
SKAT-C 2.55E-02 1.24E-03 3.60E-04 81.7 76.4
FAM225A Family with sequence similarity 225
member 1
RNA gene SKAT-C 3.86E-05 5.28E-02 2.87E-05 -- --
FBXO47 F-box only protein 47 Protein-
coding
SKAT-C 2.17E-03 3.69E-02 8.36E-04 43.8 28.3
GLIPR1 Glioma pathogenesis-related protein 1 Protein-
coding
eFBAT-MM 2.85E-02 2.88E-03 8.55E-04 57.6 34.9
KPNA1 Karyopherin alpha-1 Protein-
coding
eFBAT-MM 5.37E-02 1.50E-03 8.41E-04 82.4 77.8
LEXM
(C1orf177)
Chromosome 1 open reading frame 177 Protein-
coding
SKAT-C 2.52E-04 4.19E-02 1.32E-04 41.4 16.1
LINC00207 Long intergenic non-protein coding
RNA 207
RNA gene eFBAT-MM 2.01E-02 2.86E-03 6.17E-04 -- --
LOC100287036 Uncharacterized LOC100287036 Protein-
coding
SKAT-C 6.34E-03 2.49E-03 1.90E-04 No
Data
No
data
MAP4K3 Mitogen-activated protein kinase kinase
kinase 3
Protein-
coding
eFBAT-MM 1.56E-03 2.11E-02 3.74E-04 76.1 76.9
MBNL1 Muscleblind-like splicing regulator 1 Protein-
coding
eFBAT-MM 3.29E-02 3.70E-04 1.50E-04 66.9 78.2
NCAPG Non-SMC condensin 1 complex subunit
G
Protein-
coding
SKAT-C 6.79E-04 5.54E-02 4.21E-04 83.5 70.5
NDUFS1 NADH-ubiquinone oxidoreductase Fe-S
protein 1
Protein-
coding
SKAT-C 8.63E-02 8.79E-04 7.95E-04 94 97.1
PRKD2 Protein kinase D2 Protein-
coding
SKAT-C 1.17E-03 2.31E-02 3.12E-04 48.1 66.9
PSMG3 Proteasome assembly chaperone 3 Protein-
coding
SKAT-C 6.50E-02 2.55E-05 2.37E-05 79 54.1
RGS16 Regulator of G protein signaling Protein-
coding
SKAT-C 5.31E-03 6.65E-03 3.97E-04 56.4 38.9
ROR1 Receeptor tyrosine kinase-like orphan
receptor 1
Protein-
coding
eFBAT-MM 2.42E-02 2.02E-03 5.33E-04 65.6 63.5
SHD SH2 domain-containing protein D Protein-
coding
SKAT-C 6.86E-04 1.82E-02 1.53E-04 65.5 36.2
SIGLEC11 Sialic acid-binding immunoglobulin-like
lectin 11
Protein-
coding
eFBAT-MM 4.09E-03 3.10E-03 1.56E-04 36.2 No
data
a When meta-analysis with p<1E-03 is FBAT, dataset 1 = CHOP Trios and dataset 2 is PCGC Trios. When meta-analysis with p<1E-03 is SKAT, dataset
1 = CHOP-CC1 patients with a CTD and controls and dataset 2 is CHOP-CC2 patients with a CTD and controls.
b Heart expression percentile rank [18].
https://doi.org/10.1371/journal.pone.0219926.t005
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Finally, our analyses identified non-SMC condensing I complex subunit G (NCAPG, SKAT
meta-p = 4.2E-04) as a CTD candidate gene. The protein encoded by this gene forms part of
the condensin complex, which is involved in mitotic chromatin condensation [57]. Further,
our analyses indicated that genes in the MetaCore pathway map, “Chromosome condensation
in prometaphase) were also significantly enriched (FDR-adjusted p = 0.02) among genes with
association p<0.01 in our meta-analyses. In addition to NCAPG, a second member of the con-
densing complex, NCAPH (FBAT meta-p = 9.13E-03), and BAZ1B (FBAT meta-p = 5.62E-03),
which is part of the WICH chromatin remodeling complex, had meta-analysis p<0.01. The
involvement of chromatin-related genes, particularly H3K4me-H3K27me pathway genes, in
CHD etiology has been suggested by studies of de novo mutations [18]. Our findings suggest
that other classes of chromatin-modifiers may also contribute to CHDs.
We have previously conducted SNP-level (MAF�0.05) GWAS using the same datasets as in
the current gene-based analyses [20]. In our meta-analysis of the SNP-level results, we identi-
fied 36 variants with suggestive evidence of association (P�1E-5). However, no association
was genome-wide significant (P<5E-8). Further, none of the SNPs with suggestive evidence of
association were located in, or within 1kb up or downstream of, the genes with suggestive evi-
dence of association (Table 5) in the current, gene-based analyses. However, it should be noted
that the SNP-level analyses were restricted to include only common variants and used slightly
different configurations of the data. Specifically, in the SNP-level analyses we compared the
cases used in CHOP-CC2 to all available CHOP pediatric controls (N = 2,976 controls), and
the SNP-level meta-analysis was based on the combined results from CHOP-Trios,
PCGC-Trios and the case-control analyses.
To our knowledge, this is the first gene-based genome-wide analysis of CTDs that is based
on data for both common and rare variants. Because the various gene-based approaches have
different underlying assumptions, strengths and limitations, we used two different gene-based
approaches, eFBAT-MM and SKAT-C, to optimize the probability of identifying CTD-related
genes. The family-based approach, eFBAT-MM, is robust to population stratification bias, but
assumes that all variants within a gene have effects in the same direction and that the effect size
is inversely proportional to the MAF. In contrast, the case-control approach, SKAT-C, is sub-
ject to stratification bias, but does not make assumptions about the direction of association.
Therefore, SKAT-C is more powerful than eFBAT-MM when a large proportion of protective
and neutral variants are present in a gene, and the converse is true when this proportion is
small. Given the differences between the two methods, the lack of overlap in the genes identi-
fied by the two approaches is not particularly surprising.
Although the gene-based approaches used in our analyses had a lower multiple-testing bur-
den than SNP-based GWAS, the criterion for achieving statistical significance (corrected
p~2.5E-06) remained quite stringent. This, in combination with our relatively small sample
sizes, suggests that associations with true CTD-related genes may have been missed in our
analyses due to low study power. Further, the Q-Q plots for the eFBAT-MM analysis of indi-
vidual datasets (Fig 2) indicate that this test may be too conservative, which would have also
negatively impacted our power to detect a true association. Given these considerations, genes
with suggestive evidence of association (meta-p<1E-03) and pathways and processes with
FDR p<0.05 appear to be strong targets for further investigations of the genetic basis of CTDs.
In our analyses, we combined data across different CTD phenotypes, which could have
obscured associations if the etiology of the individual phenotypes is distinct. For example,
mutations in laterality genes (e.g. CFC1, FOXH1) have been observed in association with TGA
[58, 59], suggesting that at least some cases of TGA might be more appropriately classified as
laterality defects rather than CTDs. However, the preponderance of evidence suggests that the
various CTD phenotypes share common genetic underpinnings. Studies of familial recurrence
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patterns, phenotypes of patients with known genetic syndromes (e.g. 22q11.2 deletion syn-
drome) and studies in animal models all indicate that the various CTD phenotypes share
genetic risk factors. Moreover, studies of rare de novo and inherited variants in humans pro-
vide evidence that the genes involved in CHDs may be shared across even broader categories
of defects. For example, Jin et al. reported genome-wide significant excess of damaging de
novo and loss-of-function heterozygous mutations in seven genes among 2,871 patients with
CHD. Of these seven genes, mutations in six were observed across broad CHD categories (i.e.
CTDs, left-sided lesions and/or other CHDs) [17]. Hence, while studies of CTDs as a group
might miss phenotype-specific associations, such studies appear to be appropriate for genes
that contribute broadly to CHD risk and for genes that influence the spectrum of CTDs.
In summary, our genome-wide, gene-based analyses of common and rare variants identi-
fied enriched pathways and biological processes and candidate genes for CTDs. Our findings
provide evidence for new CTD-related candidate genes, as well as support and expand on
prior evidence implicating chromatin-related genes and splicing-regulators as determinants of
CHD risk.
Conclusions
To our knowledge, this is the first study reporting the results of gene-based, genome-wide
association studies for CTDs. The results of our study provide evidence for eight CTD candi-
date genes, of which four have previously been implicated in heart development and four are
novel candidates. Thus, these findings add to our understanding of the complex, genetic etiol-
ogy of CTDs, which may, in turn, enhance our ability to understand, predict and ultimately
improve clinical outcomes for this patient population.
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